SCHEMBL12433005

SCHEMBL12433005

CCCC(=O)[C@@H](N)Cc1ccccc1

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC15A1 P46059 2/20 0.72
LTA4H P09960 1/20 0.68
ALPI P09923 1/20 0.61
PKM P14618 1/20 0.61
PTGS1 P23219 1/20 0.61
XIAP P98170 1/20 0.61
SLC7A5 Q01650 1/20 0.61
CTSC P53634 2/20 0.49
SLC1A3 P43003 2/20 0.49
SLC1A2 P43004 2/20 0.49
SLC1A1 P43005 2/20 0.49
ACE P12821 1/20 0.48
ANPEP P15144 1/20 0.48
RNPEP Q9H4A4 1/20 0.48
DNPEP Q9ULA0 1/20 0.48
HDAC8 Q9BY41 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15244990 1.00 SLC15A1 (0.72) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL20630639 1.00 SLC15A1 (0.72) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL13515476 0.90 LTA4H (0.73) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL16657025 0.87 LTA4H (0.69) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL30008647 0.87 LTA4H (0.69) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL23762564 0.85 SLC15A1 (0.66) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL12016556 0.85 SLC15A1 (0.66) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL883466 0.85 SLC15A1 (0.66) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL11124554 0.84 SLC15A1 (1.00) SLC15A1LTA4HALPIPKMPTGS1
SCHEMBL11124557 0.84 SLC15A1 (1.00) SLC15A1LTA4HALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107820499-B Antiviral compounds, process for their preparation, and their use for the treatment of viral infections 鲁汶大学研究与开发部 2022-11-11 CN disclosed
EP-2720715-B1 VACCINE COMPOSITION COMPRISING AN INACTIVATED CHIKUNGUNYA VIRUS STRAIN BHARAT BIOTECH INT LTD (IN) 2017-08-09 EP disclosed
WO-2014011928-A1 PROCESSES AND COMPOSITIONS FOR METHYLATION-BASED ENRICHMENT OF FETAL NUCLEIC ACID FROM A MATERNAL SAMPLE USEFUL FOR NON-INVASIVE PRENATAL DIAGNOSES SEQUENOM, INC. (US) 2014-01-16 WO disclosed
US-20110190371-A1 GENETIC SUPPRESSION AND REPLACEMENT OPTIGEN PATENTS LIMITED (IE) 2011-08-04 US disclosed
US-20080108606-A1 Conjugated psychotropic drugs and uses thereof RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2008-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108606-A1 Conjugated psychotropic drugs and uses thereof SLC18A2, SLC6A3, SLCO1B3 SLC15A1 233/4885LTA4H 1794/4885ALPI 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.